Company Snapshot

Phan Anh Medical Equipment Co., Ltd. is a Vietnam-based enterprise engaged in the production and trading of medical devices, operating as an integrated industry-and-trade entity with dual roles in manufacturing and distribution. Its core function centers on sourcing, assembling, and exporting medical consumables and instruments—primarily to Asian and emerging-market partners. Structurally, it relies heavily on Chinese suppliers (71.65% of trade volume) and maintains long-standing commercial relationships with key vendors in Russia, Pakistan, and Malaysia. A notable shift occurred in late 2024: all top export ports—including Shanghai, Karachi, and Nhava Sheva—transitioned to "lost" status, indicating a complete reconfiguration of logistics infrastructure or supply chain routing as of Q1 2025.

Company Profile Information

Trade Trend Analysis

Data interpretation reveals extreme volatility in monthly transaction volumes—from 355,610 units in September 2025 to 11.7 million in April 2026—a 32.8× swing over 12 months. This reflects either seasonal procurement cycles, contract-driven bulk shipments, or inventory build-up ahead of regulatory deadlines. The absence of consistent monthly patterns and high frequency of large-volume transactions (e.g., 239 shipments in April 2026) suggest order aggregation rather than steady replenishment. From a risk perspective, this volatility signals exposure to demand shocks and limited buffer capacity in working capital planning.

Trade Partner Analysis

Data interpretation shows overwhelming concentration: Ningbo Greetmed Medical Instruments Co., Ltd. accounts for nearly half (49.48%) of all transactions, forming a dominant bilateral axis that defines the company’s operational rhythm. Three other Chinese firms—Sintrue, Joan Import & Export, and Ancheng—collectively contribute >25% of activity, reinforcing deep structural dependency on Zhejiang-based OEMs. Meanwhile, non-Chinese partners (e.g., Electro Bismed in Pakistan, Abena Asia in Malaysia) exhibit lower frequency but higher strategic diversity—suggesting deliberate market diversification beyond China-sourced goods. From a risk perspective, overreliance on a single supplier introduces acute vulnerability to geopolitical or logistical disruptions in China’s Ningbo region.

HS Code Analysis

Data interpretation highlights strong focus on Class II–III invasive devices: HS 90189090 (other electro-medical apparatus) and 90183990 (other diagnostic instruments) dominate—representing 38.7% of all transactions—indicating specialization in reusable or semi-disposable diagnostic tools and monitoring accessories. High-frequency codes like 39269039 (rubber tubing) and 30059090 (sterile wound dressings) confirm complementary consumables strategy. The presence of 85394900 (electrical connectors) and 70179000 (glass thermometers) suggests vertical integration into component-level assembly. From a risk perspective, heavy weighting toward regulated HS categories increases exposure to evolving ASEAN/MOH registration requirements and pre-market approval delays.

Trade Region Analysis

Data interpretation confirms China as the absolute anchor—accounting for 71.65% of transaction count—with no other region exceeding 15%. Pakistan (14.22%), India (3.85%), and Malaysia (4.19%) form a secondary tier of stable, medium-frequency markets. Notably, Hong Kong appears as a newly active region (2.12%, “Added” status), possibly serving as a re-export hub or compliance gateway for Western-facing exports. The “Other” category (0.22%) reflects nascent outreach—likely pilot shipments to LATAM or Africa. From a risk perspective, geographic overconcentration limits resilience against regional trade barriers, such as Vietnam’s tightening import controls on unregistered Chinese medical devices effective Q2 2025.

Contact Information

• Official Website: https://www.pharmed.vn
• Email: pharmed@pharmed.vn, import.phananh@gmail.com
• Social Media: Facebook Page
• Business Registration (MST): 0313080469 (MASOTHUE.COM)
• Regulatory File: IMDA MOH License Upload #00010719

Company Trade Summary

• Dominant China-centric sourcing model with acute supplier concentration (Ningbo Greetmed alone = 49.5% of transactions).
• Core product portfolio aligns with ASEAN-regulated Class II–III medical devices—especially catheters, endoscopes, and diagnostic accessories.
• Logistics infrastructure underwent full reset in late 2024: all top ports shifted to "lost", implying new fulfillment hubs or third-party logistics partnerships.
• Emerging regional traction in Hong Kong and Turkey signals deliberate expansion beyond traditional Asian corridors.
• Regulatory readiness is critical: 8 of top 10 HS codes require MOH IMDA registration—non-compliance risks shipment rejection at Vietnamese ports.